Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTF8CQI)

• DTT Name: Tumor necrosis factor (TNF) DTT Info
• Gene Name: TNF

Molecule-Related Drug & Molecule List

10 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[1]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[2]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[3]
Etanercept	DMCV109	Arthritis	FA20	Approved	[4]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[5]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[6]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[7]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[8]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[9]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[10]

31 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABP 501	DM2J4YB	Rheumatoid arthritis	FA20	Phase 3	[11]
AVT02	DM4CWNN	Plaque psoriasis	EA90.0	Phase 3	[12]
CPL-7075	DM62E7C	Diffuse systemic sclerosis	4A42.1	Phase 3	[13]
Golnerminogene pradenovac	DMKWV4B	Esophageal cancer	2B70	Phase 3	[14]
PF-06410293	DM2GF14	Rheumatoid arthritis	FA20	Phase 3	[15]
PF-06438179	DMM4C95	Rheumatoid arthritis	FA20	Phase 3	[16]
ABBV-154	DMVWLET	Crohn disease	DD70	Phase 2	[17]
ABT-122	DM23UQ9	Psoriatic arthritis	FA21	Phase 2	[18]
AN0128	DMT3S10	Atopic dermatitis	EA80	Phase 2	[19]
AP-301-IH	DM3ICYL	Pneumonia	CA40	Phase 2	[20]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[21]
DLX-105	DMDJUWG	Osteoarthritis	FA00-FA05	Phase 2	[22]
ESBA-105	DMYZWDC	Ocular disease	1F00.1Z	Phase 2	[23]
Ortataxel	DM1EK5D	Solid tumour/cancer	2A00-2F9Z	Phase 2	[24]
Pegsunercept	DMTDANB	Rheumatoid arthritis	FA20	Phase 2	[25]
RDP58	DM4CIKA	Diarrhea	ME05.1	Phase 2	[26]
TNF alpha kinoid	DM3AIF7	Autoimmune diabetes	5A10	Phase 2	[27]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[28]
ART621	DMI17NX	Psoriasis vulgaris	EA90	Phase 1/2	[29]
XTMAB-16	DMPSNSC	Sarcoidosis	4B20.5	Phase 1/2	[30]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[31]
AST-005	DMCN7WI	Psoriasis vulgaris	EA90	Phase 1	[32]
AVX-470	DMAKD0I	Inflammatory bowel disease	DD72	Phase 1	[31]
CYT-609	DMJ83Z7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[33]
IA-14069	DM15SXV	Rheumatoid arthritis	FA20	Phase 1	[34]
INB03	DMCQTLG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[35]
PF-05230905	DM7OC9K	Rheumatoid arthritis	FA20	Phase 1	[36]
PMI-005	DMY9XWB	Osteoarthritis	FA00-FA05	Phase 1	[37]
SAR441566	DMG2YW2	Inflammation	1A00-CA43.1	Phase 1	[38]
SAR442970	DM3DHWE	Inflammation	1A00-CA43.1	Phase 1	[39]
SAR444419	DMQICTG	Inflammation	1A00-CA43.1	Phase 1	[39]

10 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CDP571	DM4HGMX	Crohn disease	DD70	Discontinued in Phase 3	[40]
Segard	DMIHQZ8	Sepsis	1G40-1G41	Discontinued in Phase 3	[41]
Camobucol	DMS3ECJ	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[42]
CRx-191	DMB9QSJ	Psoriatic disorder	EA90	Discontinued in Phase 2	[43]
AME-527	DMR8XEN	Rheumatoid arthritis	FA20	Discontinued in Phase 1/2	[44]
CYT-007-TNFQb	DMKFIBH	Allergic rhinitis	CA08.0	Discontinued in Phase 1/2	[45]
ALS-00T2-0501	DM2QMKJ	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[46]
FR-133605	DMXWL0N	Arthritis	FA20	Terminated	[49]
MDL-201112	DMMG1K3	Colitis	1A40.Z	Terminated	[50]
TNFQb therapeutic vaccines	DMTNB6G	Crohn disease	DD70	Terminated	[45]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABX-0401	DMKUPW0	Inflammatory bowel disease	DD72	Preclinical	[47]
Celastrol	DMWQIJX	Motor neurone disease	8B60	Preclinical	[48]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[51]
DOM-0215	DMXJOYH	Discovery agent	N.A.	Investigative	[52]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[53]
PKF-241-466	DM04C9V	Discovery agent	N.A.	Investigative	[54]
PKF-242-484	DMNDLAS	Discovery agent	N.A.	Investigative	[54]
Y-39041	DMC95YB	Discovery agent	N.A.	Investigative	[55]

References

• [1] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [2] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [3] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [4] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [7] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [8] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [9] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [10] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [11] Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30.
• [12] AVT02: An Adalimumab Biosimilar. Clin Drug Investig. 2022 Oct;42(10):875-878.
• [13] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [14] TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
• [15] Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20.
• [16] Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7.
• [17] Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC). J Med Chem. 2023 Sep 14;66(17):12544-12558.
• [18] DOI: 10.1136/annrheumdis-2015-eular.4042
• [19] Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res. 2008 Feb;87(2):148-52.
• [20] AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013 Jun;26(3):356-63.
• [21] Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8.
• [22] Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol Pharmacol. 2003 Mar;63(3):690-8.
• [23] Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8.
• [24] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [25] Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008 May;172(5):1411-8.
• [26] RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 Nov;51(11):522-31.
• [27] Modulation of Anti-Tumor Necrosis Factor Alpha (TNF-alpha) Antibody Secretion in Mice Immunized with TNF-alpha Kinoid. Clin Vaccine Immunol. 2012 May; 19(5): 699-703.
• [28] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [29] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [30] Clinical pipeline report, company report or official report of Xentria
• [31] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [32] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [33] Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 December 15; 16(24): 6139-6149.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [35] Clinical pipeline report, company report or official report of INmune Bio.
• [36] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033173)
• [37] US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
• [38] An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Front Pharmacol. 2022 Nov 16;13:1037983.
• [39] Clinical pipeline report, company report or official report of Sanofi
• [40] CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo... Aliment Pharmacol Ther. 2006 Mar 1;23(5):617-28.
• [41] Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med. 2001 Apr;29(4):765-9.
• [42] AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel ... J Pharmacol Exp Ther. 2005 May;313(2):492-501.
• [43] CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
• [44] IND Filed for AME-527, Monoclonal Antibody That Is a Potential Treatment for Rheumatoid Arthritis. P&T Community. 2015.
• [45] Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465.
• [46] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [47] US patent application no. 8007,790, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
• [48] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [49] Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol. 1996 Oct;23(10):1778-83.
• [50] Effect of the carbocyclic nucleoside analogue MDL 201,112 on inhibition of interferon-gamma-induced priming of Lewis (LEW/N) rat macrophages for enhanced respiratory burst and MHC class II Ia+ antigen expression. J Leukoc Biol. 1994 Aug;56(2):133-44.
• [51] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [52] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [53] Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
• [54] Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93.
• [55] A novel anti-rheumatic drug suppresses tumor necrosis factor-alpha and augments interleukin-10 in adjuvant arthritic rats. Eur J Pharmacol. 2000 Dec 15;409(3):331-5.